Leukemia‐derived exosomes: Bringing oncogenic signals to blood cells

Mirzaei, Hossein; Shafiee, Alimohammad; Molavi, Ghader; Razi, Ebrahim; Mousavi, Nousin; Sarvizadeh, Mostafa; Taghizadeh, Mohsen

doi:10.1002/jcb.29018

Cited by 9 publications

(7 citation statements)

References 112 publications

(198 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, exosomes have also been isolated from leukemic cells and can be utilized as prognostic, diagnostic and therapeutic biomarkers in different hematologic neoplasms, such as acute myeloid leukemia, multiple myeloma and chronic lymphocytic leukemia. [71][72][73][74] Microvesicles released by the K562 cell line have been reported to contain both BCR-ABL1 DNA and transcript and are able to induce the CML phenotype in transplanted rats, or can activate BM mesenchymal stem cells promoting leukemic cells proliferation. 75,76 Few data are available on the identification and quantification of BCR-ABL1 in exosomes from CML patients, generally isolated from PB.…”

Section: Bcr-abl1 Transcript Monitoring By Digital Pcr (Dpcr)mentioning

confidence: 99%

<p>Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances</p>

Cumbo

Anelli

Specchia

et al. 2020

CMAR

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1 fusion gene generation as a consequence of the t(9;22)(q34;q11) rearrangement. The identification of the BCR-ABL1 transcript was of critical importance for both CML diagnosis and minimal residual disease (MRD) monitoring. In this review, we report the recent advances in the CML MRD monitoring based on RNA, DNA and protein analysis. The detection of the BCR-ABL1 transcript by the quantitative reverse-transcriptase polymerase chain reaction is the gold standard method, but other systems based on digital PCR or on GeneXpert technology have been developed. In the last years, DNA-based assays showed high sensitivity and specificity, and flow cytometric approaches for the detection of the BCR-ABL1 fusion protein have also been tested. Recently, new MRD monitoring systems based on the detection of molecular markers other than the BCR-ABL1 fusion were proposed. These approaches, such as the identification of CD26+ leukemic stem cells, microRNAs and mitochondrial DNA mutations, just remain preliminary and need to be implemented. In the precision medicine era, the constant improvement of the CML MRD monitoring practice could allow clinicians to choose the best therapeutic algorithm and a more accurate selection of CML patients eligible for the tyrosine kinase inhibitors discontinuation.

show abstract

Section: Bcr-abl1 Transcript Monitoring By Digital Pcr (Dpcr)mentioning

confidence: 99%

<p>Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances</p>

Cumbo

Anelli

Specchia

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…However, certain groups have revealed that exosomes isolated from cell line cultures modulate the crosstalk between leukemia cells and the bone marrow (BM) microenvironment, and that they also carry molecular tumor markers (21)(22)(23)(24). Moreover, recent studies have indicated that leukemia-derived exosomes can be utilized as prognostic (25), diagnostic (26) and therapeutic biomarkers (27) for individuals suffering from different hematologic malignancies, such as acute myeloid leukemia (28)(29)(30), multiple myeloma (31) and chronic lymphocytic leukemia (32).…”

Section: Introductionmentioning

confidence: 99%

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

due to the discovery of their role in intra-cellular communications, exosomes, which carry information specific to the cell of origin, have garnered considerable attention in cancer research. Moreover, there is evidence to suggest the possibility of isolating different exosome sub-populations based on target antigens at the cell surface. Philadelphia chromosome-positive (Ph +) chronic myeloid leukemia (cML) is a clonal myeloproliferative neoplasia characterized by the breakpoint cluster region-proto-oncogene 1 tyrosine-protein kinase (BcR-ABL1) fusion-gene, derived from the t (9;22) translocation. Tyrosine kinase inhibitors (TKIs) target BcR-ABL1 protein and induce major or deep molecular responses in the majority of patients. despite the fact that several studies have demonstrated the persistence of leukemic cells in the bone marrow niche, even following treatment, TKIs prolong patient survival time and facilitate treatment-free remission. These characteristics render cML a plausible model for investigating the feasibility of tumor-derived exosome fraction enrichment. In the present study, patients in the chronic phase (cP) of CML were treated with TKIs, and the quantification of the BCR-ABL1 exosomal transcript was performed using digital PcR (dPcR). The possibility of tumor-derived exosomes enrichment was confirmed, and for the first time, to the best of our knowledge, the detection of the BcR-ABL1 transcript highlighted the presence of active leukemic cells in patients with CP-CML. According to these findings, tumor-derived exosomes may be considered a novel tool for the identification of active leukemic cells, and for the assessment of innovative monitoring focused on the biological functions of exosomes in cML.

show abstract

“…Exosomes, as biological vehicles, could participate in the regulation of leukemia by transferring oncogenic signals to blood cells (24). Exosomal long non-coding RNAs (lncRNAs) could act as potential targets for the detection of different types of cancer (25).…”

Section: Discussionmentioning

confidence: 99%

Exosome‑transmitted long non‑coding RNA CRNDE promotes chronic myeloid leukemia progression and drug‑resistance

Zhou

Zhang

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

Leukemia‐derived exosomes: Bringing oncogenic signals to blood cells

Cited by 9 publications

References 112 publications

<p>Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances</p>

<p>Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances</p>

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

Exosome‑transmitted long non‑coding RNA CRNDE promotes chronic myeloid leukemia progression and drug‑resistance

Contact Info

Product

Resources

About